Roche developed the Avenio kit in collaboration with its subsidiary, Foundation Medicine. The CGP kit offers information on genomic signatures like tumor mutational burden, microsatellite instability and loss of heterozygosity. The Avenio kit uses a gene panel based on the FoundationOne platform. It runs on Illumina's NextSeq 500/5500 RUO and NextSeq 550 Dx systems, Roche said. One kit can handle 24 samples and produces results in five days.

The Avenio Tumor Tissue CGP kit is a research-use-only next-generation sequencing test that provides an end-to-end workflow from DNA extraction and library preparation to the generation of variant results by the FoundationOne analysis platform via Avenio Connect. The kit uses a gene panel based on the FoundationOne platform that was designed to match the FoundationOne CDx panel content to analyze 324 cancer-related genes across four main classes of genomic alterations and genomic signatures known to cause and drive cancer. These genes provide valuable genomic insights and deepen the understanding of cancer biology.

The firm plans to launch Avenio in Asia, Europe, North America, and South America.